乙型肝炎病毒基因型用干扰素α-2b联合苦参素治疗的临床研究

目的：研究乙型肝炎病毒基因型用干扰素α-2b联合苦参素治疗慢性乙型肝炎疗效的关系。方法：应用免疫荧光定量方法检测60例慢性乙型肝炎（慢乙肝）的乙肝病毒基因型，患者均在常规保肝治疗基础上应用干扰素α-2b和苦参素联合抗病毒治疗，疗程6个月。随访6个月。结果：治疗结束及随访6个月时血清HBeAg／HBeAb转换率、HBVDNA阴转率、HBVDNA降低2—5logL率为B基因型组分别为83.3％、83.3％、16．67％；66．67％、75．00％、25．00％；C基因型组分别为45．83％、47．92％、45．65％；35．42％、39．58％、41．67％。B基因型组与C基因型组比较．血清HBeAg／HBeAb转换率、HBVDNA阴转率、血清转氨酶及肝纤维化指标下降均有统计学意义（P〈0．05）。结论：干扰素α-2b联合苦参素治疗慢性乙型肝炎疗效及随访观察疗效B基因型优于C基因型。

Clinical study of hepatitis B virus genotypes and therapeutic effect of interferon 2-2b combined with matrine in chronic hepatitis B

Objective:To study the hepatitis B virus genotypes and their relationship with the therapeutic effect of interferon 2-2b combined with matrine in chronic hepatitis B.Methods:The hepatitis B virus genotype in 60 cases of chronic hepatitis B was detected respectively by immunofluorescence quantitative analysis.And based on the routine liver-protective treatment,all patients were given an associated antiveral therapy of interferon 2-2b and matrine for 6 months.The follow-up time was also 6 months.Results:At the end of treatment and follow-up,the transformation rates of serum HBeAg/HBeAb,the negative rates of serum HBV DNA and the depressed rates of serum HBV DNA in genotype B group were 83.3%,83.3%,16.67%,66.67%,75.00%,25.00% respectively,and thos in genotype c group were 45.92%,45.65%,35.42%,35.58%,41.67% respectively.The serum ALT,AST and hepatic fibrosis of the patients in genotype B group showed significantly lower than those in genotype c group.There was significant difference in the therapeutic effect between two groups(P<0.05).Conclusion:The clinical therapeutic effect of interferon 2-2b combined with matrine is very good for chronic hepatitis B,and the clinical therapeutic effect of genotype B is superior to that of genotype C.